Compare STRIDES PHARMA SCIENCE with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs GLENMARK PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE GLENMARK PHARMA STRIDES PHARMA SCIENCE/
GLENMARK PHARMA
 
P/E (TTM) x 16.1 12.5 129.1% View Chart
P/BV x 1.0 1.8 53.4% View Chart
Dividend Yield % 0.5 0.5 94.1%  

Financials

 STRIDES PHARMA SCIENCE   GLENMARK PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
GLENMARK PHARMA
Mar-19
STRIDES PHARMA SCIENCE/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,147712 161.2%   
Low Rs642484 132.8%   
Sales per share (Unadj.) Rs317.2349.6 90.7%  
Earnings per share (Unadj.) Rs7.832.8 23.9%  
Cash flow per share (Unadj.) Rs25.144.3 56.5%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.20.3 66.8%  
Book value per share (Unadj.) Rs274.3198.6 138.1%  
Shares outstanding (eoy) m89.50282.17 31.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.81.7 165.0%   
Avg P/E ratio x114.018.2 625.5%  
P/CF ratio (eoy) x35.713.5 264.8%  
Price / Book Value ratio x3.33.0 108.4%  
Dividend payout %25.56.1 417.9%   
Avg Mkt Cap Rs m80,058168,625 47.5%   
No. of employees `0002.512.0 20.8%   
Total wages/salary Rs m4,34120,561 21.1%   
Avg. sales/employee Rs Th11,325.88,196.0 138.2%   
Avg. wages/employee Rs Th1,731.41,708.1 101.4%   
Avg. net profit/employee Rs Th280.1768.5 36.4%   
INCOME DATA
Net Sales Rs m28,39498,655 28.8%  
Other income Rs m9412,081 45.2%   
Total revenues Rs m29,334100,736 29.1%   
Gross profit Rs m3,96515,858 25.0%  
Depreciation Rs m1,5403,259 47.3%   
Interest Rs m1,9623,346 58.7%   
Profit before tax Rs m1,40311,335 12.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4361,672 -26.1%   
Tax Rs m973,756 2.6%   
Profit after tax Rs m7029,250 7.6%  
Gross profit margin %14.016.1 86.9%  
Effective tax rate %6.933.1 20.9%   
Net profit margin %2.59.4 26.4%  
BALANCE SHEET DATA
Current assets Rs m24,83666,968 37.1%   
Current liabilities Rs m18,99340,211 47.2%   
Net working cap to sales %20.627.1 75.9%  
Current ratio x1.31.7 78.5%  
Inventory Days Days7183 85.2%  
Debtors Days Days11381 139.7%  
Net fixed assets Rs m34,28933,322 102.9%   
Share capital Rs m895282 317.2%   
"Free" reserves Rs m23,65155,770 42.4%   
Net worth Rs m24,54656,052 43.8%   
Long term debt Rs m15,51335,738 43.4%   
Total assets Rs m65,437132,888 49.2%  
Interest coverage x1.74.4 39.1%   
Debt to equity ratio x0.60.6 99.1%  
Sales to assets ratio x0.40.7 58.4%   
Return on assets %4.19.5 43.0%  
Return on equity %2.916.5 17.3%  
Return on capital %6.917.8 38.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69762,998 24.9%   
Fx outflow Rs m73522,859 3.2%   
Net fx Rs m14,96240,140 37.3%   
CASH FLOW
From Operations Rs m1,87113,242 14.1%  
From Investments Rs m5,826-6,990 -83.3%  
From Financial Activity Rs m-10,157-7,387 137.5%  
Net Cashflow Rs m-2,615-2,971 88.0%  

Share Holding

Indian Promoters % 27.7 48.3 57.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 6.9 547.8%  
FIIs % 8.6 34.4 25.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 10.5 246.7%  
Shareholders   56,241 56,727 99.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  SUVEN LIFESCIENCES  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Sep 13, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS